Article Details

Zacks Investment Research Downgrades Corvus Pharmaceuticals (NASDAQ:CRVS) to Sell

Retrieved on: 2020-12-26 00:00:00

Tags for this article:

Click the tags to see associated articles and topics

Zacks Investment Research Downgrades Corvus Pharmaceuticals (NASDAQ:CRVS) to Sell. View article details on hiswai:

Excerpt

Morgan Stanley now owns 32,746 shares of the company's stock valued at $131,000 after acquiring an additional 17,704 shares during the period.

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up